methamphetamine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1732 537-46-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • methamphetamine
  • (S)-Methamphetamine
  • methylamphetamine
  • D-Methylamphetamine
  • methamphetamine hydrochloride
  • metamfetamine
  • methamphetamine HCl
A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.
  • Molecular weight: 149.24
  • Formula: C10H15N
  • CLOGP: 1.89
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 12.03
  • ALOGS: -2.21
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 0 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1000 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 40 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.92 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 67 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 4.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.85 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 12 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 31, 1943 FDA RECORDATI RARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 2848.02 52.88 673 2331 62735 46620323
Toxicity to various agents 984.50 52.88 398 2606 211368 46471690
Completed suicide 381.09 52.88 185 2819 145735 46537323
Cardio-respiratory arrest 186.08 52.88 86 2918 59783 46623275
Death 181.23 52.88 158 2846 335390 46347668
Respiratory arrest 158.64 52.88 65 2939 33751 46649307
Cardiac arrest 149.84 52.88 85 2919 90314 46592744
Intentional product misuse 102.08 52.88 53 2951 47075 46635983
Poisoning 76.22 52.88 30 2974 13964 46669094
Substance abuse 66.57 52.88 20 2984 4147 46678911
Drug screen positive 63.57 52.88 19 2985 3872 46679186

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 3550.56 53.76 1030 3944 81042 29866462
Toxicity to various agents 1487.12 53.76 667 4307 176516 29770988
Completed suicide 288.69 53.76 188 4786 99304 29848200
Respiratory arrest 251.79 53.76 114 4860 29144 29918360
Cardio-respiratory arrest 236.85 53.76 136 4838 57170 29890334
Cardiac arrest 174.78 53.76 135 4839 92715 29854789
Drug abuser 141.34 53.76 45 4929 4356 29943148
Overdose 115.32 53.76 102 4872 84235 29863269
Poisoning 102.92 53.76 46 4928 11336 29936168
Intentional product misuse 98.67 53.76 65 4909 34602 29912902
Death 95.82 53.76 193 4781 357090 29590414
Accidental overdose 85.01 53.76 47 4927 18228 29929276
Incorrect route of product administration 84.35 53.76 40 4934 11275 29936229
Drug screen positive 71.22 53.76 27 4947 4380 29943124
Substance abuse 62.17 53.76 28 4946 7012 29940492
Brain oedema 60.71 53.76 33 4941 12365 29935139

Pharmacologic Action:

SourceCodeDescription
ATC N06BA03 NERVOUS SYSTEM
PSYCHOANALEPTICS
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
Centrally acting sympathomimetics
FDA CS M0001015 Amphetamines
FDA PE N0000175372 Appetite Suppression
FDA EPC N0000175425 Amphetamine Anorectic
FDA PE N0000175651 Increased Sympathetic Activity
FDA PE N0000175729 Central Nervous System Stimulation
FDA EPC N0000175739 Central Nervous System Stimulant
MeSH PA D018663 Adrenergic Agents
MeSH PA D018759 Adrenergic Uptake Inhibitors
MeSH PA D002491 Central Nervous System Agents
MeSH PA D000697 Central Nervous System Stimulants
MeSH PA D015259 Dopamine Agents
MeSH PA D018765 Dopamine Uptake Inhibitors
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D013566 Sympathomimetics
CHEBI has role CHEBI:35337 analeptic drug
CHEBI has role CHEBI:35471 psychopharmaceuticals
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:50910 agente neurotoxico
CHEBI has role CHEBI:78298 environmental contaminants

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Attention deficit hyperactivity disorder indication 406506008
Obesity indication 414916001 DOID:9970
Gilles de la Tourette's syndrome contraindication 5158005 DOID:11119
Suicidal thoughts contraindication 6471006
Dependent drug abuse contraindication 6525002
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Bipolar disorder contraindication 13746004 DOID:3312
Hepatic encephalopathy contraindication 13920009 DOID:13413
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Feeling agitated contraindication 24199005
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Hyperactive behavior contraindication 44548000
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Anorexia nervosa contraindication 56882008 DOID:8689
Hepatic failure contraindication 59927004
Aggressive behavior contraindication 61372001
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Arteriosclerotic vascular disease contraindication 72092001
Hepatic coma contraindication 72836002 DOID:12550
Sleep apnea contraindication 73430006 DOID:0050847
Cardiomyopathy contraindication 85898001 DOID:0050700
Weight loss contraindication 89362005
Kidney disease contraindication 90708001 DOID:557
Structural disorder of heart contraindication 128599005
Seizure disorder contraindication 128613002
Motor tic disorder contraindication 230337001
Cerebrovascular accident contraindication 230690007
Mania contraindication 231494001
Disease of liver contraindication 235856003 DOID:409
Sleep automatism contraindication 247962006
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Cardiovascular event risk contraindication 395112001
Visual impairment contraindication 397540003
Respiratory insufficiency contraindication 409623005
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Porphyria contraindication 418470004
Hypertensive urgency contraindication 443482000
Acute exacerbation of asthma contraindication 708038006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.73 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent dopamine transporter Transporter INHIBITOR Ki 7.61 PDSP CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 5.08 CHEMBL
5-hydroxytryptamine receptor 2B GPCR Ki 5 PDSP
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 6.13 PDSP
Alpha-2C adrenergic receptor GPCR Ki 6.09 PDSP
Alpha-2B adrenergic receptor GPCR Ki 6.13 PDSP
Alpha-2A adrenergic receptor GPCR Ki 5.38 PDSP
Trace amine-associated receptor 1 GPCR AGONIST EC50 5.89 CHEMBL
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Ki 7.91 PDSP
Trace amine-associated receptor 1 GPCR EC50 6.88 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 7.15 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 5.28 CHEMBL
Synaptic vesicular amine transporter Transporter Ki 5.61 CHEMBL

External reference:

IDSource
4019821 VUID
N0000147910 NUI
D02242 KEGG_DRUG
51-57-0 SECONDARY_CAS_RN
4018483 VANDF
4019821 VANDF
C0025611 UMLSCUI
CHEBI:6809 CHEBI
B40 PDB_CHEM_ID
10836 PUBCHEM_CID
CHEMBL1201201 ChEMBL_ID
CHEMBL1200952 ChEMBL_ID
D008694 MESH_DESCRIPTOR_UI
DB01577 DRUGBANK_ID
4803 IUPHAR_LIGAND_ID
1879 INN_ID
44RAL3456C UNII
6816 RXNORM
1988 MMSL
5066 MMSL
d00805 MMSL
001797 NDDF
004722 NDDF
387329009 SNOMEDCT_US
387499002 SNOMEDCT_US
8692006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Methamphetamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-0389 TABLET 5 mg ORAL ANDA 25 sections
Desoxyn HUMAN PRESCRIPTION DRUG LABEL 1 55292-102 TABLET 5 mg ORAL NDA 25 sections
Desoxyn HUMAN PRESCRIPTION DRUG LABEL 1 55292-104 TABLET 5 mg ORAL NDA 25 sections
Methamphetamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68308-115 TABLET 5 mg ORAL ANDA 29 sections